Clinical Trials Browser

Phase 3 × INDUSTRY × sipuleucel-T × Clear all

NCT03686683 2024-10-08

ProVent

Phase 3 Completed

532 enrolled 14 charts

Adenocarcinoma of the Prostate

NCT00779402 2018-01-29

PROTECT

Phase 3 Completed

176 enrolled 14 charts

Neoplasms, Prostatic Neoplasms

NCT00005947 2010-11-01

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 3 Completed

127 enrolled 9 charts

Prostatic Neoplasms

NCT01133704 2010-09-08

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

Phase 3 Completed

98 enrolled 9 charts

Hormone-Refractory Prostate Cancer

NCT00065442 2010-09-06

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Phase 3 Completed

512 enrolled 9 charts

Prostatic Neoplasms